贝伐单抗在结直肠癌靶向治疗中的临床应用分析  

The analysis to the Clinical Application of Bevacizumab in the Treatment of Colorectal Cancer Target

作　　者：黄露迷[1] 冀晓辉[1] 王春梅[1] 王东林[1] 李代蓉[1] 

机构地区：[1]重庆市肿瘤研究所肿瘤内科

出　　处：《世界最新医学信息文摘》2017年第9期11-12,共2页World Latest Medicine Information Electronic Version

摘　　要：目的探究贝伐单抗用于结直肠癌靶向治疗中的效果。方法在我院于2013年8月至2016年8月间收治的结直肠癌患者中随机抽取出46例为本次研究的观察对象,根据治疗方法的不同将患者分入到观察组和对照组中,对照组23例患者采用FOLFOX4方案化疗,观察组23例患者采用贝伐单抗联合FOLFOX4方案化疗,对比分析两组患者的治疗有效率、不良反应发生率等指标值。结果观察组患者的治疗有效率52.17%明显比对照组患者的21.74%高,P<0.05;观察组患者在中性粒细胞减少、血小板减少、恶心呕吐、蛋白尿不良反应的发生率分别为26.09%、34.78%、43.48%、8.70%;对照组分别为39.13%、39.13%、52.18%、17.39%,P>0.05。结论在结直肠癌的靶向治疗中采用贝伐单抗有助于促进肿瘤细胞的控制,提高患者的生存质量,值得推广应用。Objective To investigate the efficacy of bevacizumab in the targeted therapy of colorectal cancer. Methods In our hospital in August 2013-August 2016 colorectal cancer patients randomly chosen out of the 46 cases as the research object of observation, According to the different treatment methods will be divided into the observation group and the control group, the control group 23 patients with FOLFOX4 chemotherapy, Comparative analysis the treatment of patients with two groups of efficient and incidence of adverse reactions such as parameter values. Results The effective rate of treatment in the observation group was 52.17% higher than that of the control group,P〈0.05,〈21.74%; Observation group of patients in neutropenia, thrombocytopenia, proteinuria, nausea and vomiting, the incidence of adverse reactions were 26.09%, 34.78%, 43.48% and 8.70% respectively;The control group were 39.13%, 39.13%, 52.18%, 17.39%,P〉0.05. Conclusion Bevacizumab can promote the control of tumor cells and improve the quality of life of patients with colorectal cancer, which is worthy of popularization and application.

关 键 词：贝伐单抗 结直肠癌 靶向治疗 FOLFOX4 不良反应 

分 类 号：R574.62[医药卫生—消化系统]